| Analgesic Efficacy After Pancreatobiliary Surgery: Intravenous Versus Patient-controlled Epidural (NCT04352023) | National Cancer Center, Korea | 2018-01-01 |
| QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (NCT03387098) | ImmunityBio, Inc. | 2017-12-28 |
| A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer (NCT03331562) | Translational Genomics Research Institute | 2017-12-27 |
| Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) (NCT03410030) | HonorHealth Research Institute | 2017-12-15 |
| Shark Mouth Modified Pancreaticojejunostomy (NCT03366038) | Peking University Third Hospital | 2017-12-08 |
| Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic Cancer (NCT03374293) | Shixiu Wu | 2017-12-01 |
| Cancer of the Head of the Pancreas: Early Surgery or Preoperative Biliary Drainage? (NCT03358095) | Helsinki University Central Hospital | 2017-11-26 |
| Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy? (NCT03269994) | Memorial Sloan Kettering Cancer Center | 2017-11-21 |
| Trial of Neoadjuvant Chemotherapy With S1 Plus Paclitaxel-albumin on Pancreatic Cancer (NCT03585062) | Zhejiang Provincial People's Hospital | 2017-11-20 |
| Biliary Drainage Preceding Possible Pancreaticoduodenectomy. Are Self-expandable Metallic Stents (SEMS) Superior to Plastic Stents? (NCT03350763) | Helsinki University Central Hospital | 2017-11-18 |
| Palliative Pancreatic Duct Stenting in Patients With Inoperable Pancreatic Cancer (NCT03069664) | Helsinki University Central Hospital | 2017-11-17 |
| Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer (NCT03086642) | Karie D. Runcie, MD | 2017-11-16 |
| Personalized Precision Diagnosis and Treatment of Pancreatic Cancer (NCT04373928) | Changhai Hospital | 2017-11-10 |
| TAS-102 (Lonsurf) in Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Post First Line Chemotherapy (UF-STO-PANC-003) (NCT02921737) | University of Florida | 2017-11-09 |
| QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (NCT03329248) | ImmunityBio, Inc. | 2017-11-06 |
| A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma (NCT03250273) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2017-11-06 |
| Detection of High Expression Levels of EMT-Transcription Factor mRNAs in Patients With Pancreatic Cancer and Their Diagnostic Potential (NCT04323917) | Istituto Clinico Humanitas | 2017-11-02 |
| A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma (NCT03334708) | Memorial Sloan Kettering Cancer Center | 2017-10-30 |
| PENS or TENS for Pain in Pancreatic Cancer (NCT03331055) | Fuda Cancer Hospital, Guangzhou | 2017-10-27 |
| Clinical Study of a Personalized Neoantigen Cancer Vaccine in Treating Patients With Advanced Pancreatic Cancer (NCT03645148) | Zhejiang Provincial People's Hospital | 2017-10-24 |
| A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer (NCT03435289) | Atlantic Health System | 2017-10-19 |
| Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia (NCT03207724) | Andrew Hendifar, MD | 2017-10-16 |
| A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors (NCT03129139) | Minneamrita Therapeutics LLC | 2017-10-10 |
| Autologous CARTmeso/19 Against Pancreatic Cancer (NCT03497819) | First Affiliated Hospital of Wenzhou Medical University | 2017-10-01 |
| A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer (NCT03300921) | Abramson Cancer Center at Penn Medicine | 2017-09-28 |
| APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (NCT03175224) | Apollomics Inc. | 2017-09-27 |
| The Efficacy and Safety of K-001 in the Treatment of Advanced Pancreatic Cancer (NCT04183478) | RenJi Hospital | 2017-09-26 |
| Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer (NCT03600623) | University of Alabama at Birmingham | 2017-09-25 |
| CAR T Cell Immunotherapy for Pancreatic Cancer (NCT03323944) | University of Pennsylvania | 2017-09-15 |
| Maintenance Rucaparib in BRCA1, BRCA2 or PALB2 Mutated Pancreatic Cancer That Has Not Progressed on Platinum-based Therapy (NCT03140670) | Abramson Cancer Center at Penn Medicine | 2017-09-05 |
| Long Term Follow-Up Study for Subjects Previously Treated With Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy (NCT03165188) | NewLink Genetics Corporation | 2017-09-01 |
| SEMS Placement Before Surgery in Unblocking Bile Duct in Patients With Periampullary Pancreatic Cancer With Severe Obstructive Jaundice (NCT03820544) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2017-09-01 |
| A Study of the Efficacy of ONS to Reduce Postoperative Complications Associated With Pancreatic Surgery (NCT03244683) | Ohio State University | 2017-08-28 |
| A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma (NCT03207867) | Novartis Pharmaceuticals | 2017-08-28 |
| QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (NCT03136406) | ImmunityBio, Inc. | 2017-08-11 |
| A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors (NCT03184870) | Bristol-Myers Squibb | 2017-08-08 |
| A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism (NCT03139487) | Asan Medical Center | 2017-08-07 |
| Diet and Exercise After Pancreatic Cancer (NCT03187028) | University of Alabama at Birmingham | 2017-08-03 |
| Prevention of Chyle-leak After Major Pancreatic Surgery (NCT03167814) | Helsinki University Central Hospital | 2017-08-01 |
| Volatiles in Breath and Headspace Analysis - Diagnostic Markers (NCT03228095) | University of Latvia | 2017-07-24 |
| Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer (NCT03848182) | Albert Einstein College of Medicine | 2017-07-21 |
| A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer (NCT03167112) | Petr Kavan | 2017-07-03 |
| The Emotional Impact of Surveillance for Pancreatic Cancer (NCT04024345) | Azienda Ospedaliera Universitaria Integrata Verona | 2017-07-01 |
| Electrochemoterapy With Bleomycin for the Treatment of Unresectable Pancreatic Cancer (NCT03225781) | Universita di Verona | 2017-07-01 |
| AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas (NCT03205176) | AstraZeneca | 2017-06-30 |
| QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer (NCT03127098) | NantCell, Inc. | 2017-06-26 |
| Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma (NCT03099265) | Yale University | 2017-06-26 |
| A Phase I Trial of LY3143921 Hydrate in Solid Tumours (NCT03096054) | Cancer Research UK | 2017-06-21 |
| Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer. (NCT03267173) | First Affiliated Hospital of Harbin Medical University | 2017-06-15 |
| Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer (NCT03180437) | Fuda Cancer Hospital, Guangzhou | 2017-06-15 |
| PancFit: Multimodal Exercise During Preoperative Therapy for Pancreatic Cancer (NCT03187951) | M.D. Anderson Cancer Center | 2017-06-13 |
| A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection (NCT03038477) | University of Colorado, Denver | 2017-06-12 |
| Role of the Cystic Fluid Interleukins and Tumor Necrosis Factor (TNF) Levels in Characterizing Pancreatic Cysts Detected by Endoscopic Ultrasound (EUS) (NCT03178812) | Hillel Yaffe Medical Center | 2017-06-01 |
| RCT of Mobile Apps & FitBit v. Usual Care (NCT03623464) | Weill Medical College of Cornell University | 2017-05-31 |
| Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source (NCT02843945) | CivaTech Oncology | 2017-05-31 |
| Preoperative Detection of Lymph Node Metastases in Pancreatic and Periampullary Carcinoma Using USPIO MRI (NCT04311047) | Radboud University Medical Center | 2017-05-15 |
| Circulating Tumor DNA as a Prognostic Marker in Patients With Pancreatic Cancer (NCT03214991) | Ji Kon Ryu | 2017-05-12 |
| Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer (NCT03023722) | Yale University | 2017-05-11 |
| Evaluation of SBRT for Patients With Locally Advanced Unresectable Pancreatic Cancer (NCT03158779) | Istituto Clinico Humanitas | 2017-05-10 |
| Immunotherapy Study of Evofosfamide in Combination With Ipilimumab (NCT03098160) | Threshold Pharmaceuticals | 2017-05-10 |
| Registry for Pancreatic Cancer (NCT03001505) | Duke University | 2017-05-04 |
| Immunologic Signatures Following Surgery for Pancreatic Cancer (NCT03001518) | Duke University | 2017-05-04 |
| Effectiveness of Care in Certified Cancer Centres in Germany (NCT04334239) | Technische Universität Dresden | 2017-05-01 |
| A Study to See Whether a Nutritional Supplement is Beneficial for Patients With Pancreatic Cancer (NCT02745197) | University of Alberta | 2017-05-01 |
| Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. (NCT02947165) | Novartis Pharmaceuticals | 2017-04-25 |
| A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer (NCT02908451) | AbGenomics B.V Taiwan Branch | 2017-04-24 |
| Trial Comparing EUS-guided Radiofrequency Ablation vs. EUS-guided Celiac Plexus Neurolysis (NCT03152487) | AdventHealth | 2017-04-24 |
| Impact of Three-dimensional Visualization on Operation Strategy and Complications for Pancreatic Cancer (NCT03749005) | Zhujiang Hospital | 2017-04-18 |
| A Phase II, International Open Label Trial of Minnelide™ in Patients With Refractory Pancreatic Cancer (NCT03117920) | Minneamrita Therapeutics LLC | 2017-04-10 |
| Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers (NCT02830724) | National Cancer Institute (NCI) | 2017-04-06 |
| Familial Investigations of Childhood Cancer Predisposition (NCT03050268) | St. Jude Children's Research Hospital | 2017-04-06 |
| High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies (NCT03146962) | Weill Medical College of Cornell University | 2017-03-29 |
| Enhancing Fitness Before Pancreatic Surgery (NCT02940067) | Royal Surrey County Hospital NHS Foundation Trust | 2017-03-28 |
| PERiX: Comparison of Efficacy Between Placement of Epidural Catheters X-ray Guided and LOS Technique (NCT03685370) | Azienda Ospedaliera Universitaria Integrata Verona | 2017-03-01 |
| Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer (NCT02923921) | Eli Lilly and Company | 2017-03-01 |
| Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors (NCT03065062) | Dana-Farber Cancer Institute | 2017-02-28 |
| Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers (NCT03073473) | Cota Inc. | 2017-02-28 |
| Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy (NCT03060720) | Dana-Farber Cancer Institute | 2017-02-24 |
| Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program (NCT03475966) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2017-02-22 |
| Immune Response After Pancreatic Cancer Treatment (NCT03069599) | Insel Gruppe AG, University Hospital Bern | 2017-02-15 |
| A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (NCT03058289) | Intensity Therapeutics, Inc. | 2017-02-09 |
| FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas (NCT03042780) | H. Lee Moffitt Cancer Center and Research Institute | 2017-02-01 |
| Robotic Versus Open Surgery Following Neoadjuvant Therapy in Pancreatic Cancer: Evaluation of Safety and Oncologic Outcomes (NCT07147374) | Peking Union Medical College Hospital | 2017-02-01 |
| Colonization of Bile Ducts and Postoperative Infectious Complications of Pancreaticoduodenectomies (NCT03525067) | Central Hospital, Nancy, France | 2017-02-01 |
| Predicting Effective Therapy in Pancreatic Cancer (NCT03033927) | Memorial Sloan Kettering Cancer Center | 2017-01-24 |
| Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies (NCT02950025) | Washington University School of Medicine | 2017-01-19 |
| Coordinating and Data Management Center for the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (NCT03058926) | M.D. Anderson Cancer Center | 2017-01-19 |
| Energy Expenditure and Nutrition After Pancreatic Surgery (NCT07703813) | Evangelismos Hospital | 2017-01-10 |
| Pancreatic Resection in Fit Octogenarians With Nonmetastatic Pancreatic Cancer (NCT07542782) | Medizinische Hochschule Brandenburg Theodor Fontane | 2017-01-01 |
| Impact of Margin-accentuation IRE in Pancreatic Cancer (NCT02952859) | Insel Gruppe AG, University Hospital Bern | 2017-01-01 |
| A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer (NCT03013712) | First Affiliated Hospital of Chengdu Medical College | 2017-01-01 |
| Comparison Between Wound Vacuum Dressing and Standard Closure to Reduce Rates of Surgical Site Infections (NCT03021668) | Johns Hopkins University | 2017-01-01 |
| Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates (NCT02723331) | Academic Thoracic Oncology Medical Investigators Consortium | 2016-12-30 |
| PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer (NCT02985801) | Massimo Raimondo, M.D. | 2016-12-01 |
| Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma (NCT02743975) | University Medical Center Groningen | 2016-12-01 |
| High-activity Natural Killer Immunotherapy for Small Metastases of Pancreatic Cancer (NCT03008304) | Fuda Cancer Hospital, Guangzhou | 2016-12-01 |
| Food Reward in Cachexia Induced by Acute or Chronic Disease (NCT02798003) | Maastricht University Medical Center | 2016-12-01 |
| An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib (NCT02955940) | Incyte Corporation | 2016-11-30 |
| A Dose Escalation Trial of SBRT After Induction Chemotherapy for Locally Advanced Pancreatic Cancer (NCT02873598) | University of Colorado, Denver | 2016-11-17 |
| Gemcitabine and Capecitabine With or Without T-ChOS as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (NCT02767752) | Herlev Hospital | 2016-11-01 |